ストックスクリーナーアプリを入手
0.8771
1.00%
-0.0147
Cero Therapeutics Holdings Inc (CERO) 最新ニュース
CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com Australia
CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia - Nasdaq
Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia - marketscreener.com
CERo Therapeutics Holdings, Inc. Announces TriStar - GlobeNewswire
Leading Cancer Center to Test Revolutionary AML Treatment: CERo's Novel T Cell Therapy Enters Clinical Trial - Stock Titan
CERo Therapeutics Holdings Inc (CERO) Stock: A Year of Market Movement, Down and Up - investchronicle.com
CERo Therapeutics announces up to $8M Series D financing; shares up - MSN
CERo Therapeutics Holdings Inc [CERO] is -81.50% lower this YTD. Is it still time to buy? - dbtnews.com
Market cap of Crown LNG Holdings Limited [CGBS] reaches 59.64M – now what? - dbtnews.com
New Providence Acquisition Corp III [NPACU] Stock trading around $10.02 per share: What’s Next? - dbtnews.com
A company insider recently sold 50,896 shares of OppFi Inc [OPFI]. Should You Sale? - knoxdaily.com
CERo Therapeutics Holdings Inc [CERO] Records 50-Day SMA of $1.1308 - knoxdaily.com
CERo Therapeutics Holdings, Inc. to Present Poster on Lead - GlobeNewswire
Breakthrough Leukemia Treatment: CERo's First-in-Human Trial Results Revealed at ASCO 2025 - Stock Titan
Holdings of CERo Therapeutics Holdings Inc (CERO) are aligned with the stars - Sete News
CERo Therapeutics Holdings Inc’s Market Journey: Closing Strong at 1.11, Up 38.85 - DWinneX
Market Momentum: Haoxin Holdings Ltd (HXHX) Registers a 16.47 Increase, Closing at 1.98 - DWinneX
CERo Therapeutics (NASDAQ:CERO) Upgraded at D Boral Capital - Defense World
CERo Therapeutics begins Phase 1 trial for AML treatment By Investing.com - Investing.com South Africa
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat ResultsASGN (NYSE:ASGN), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook - Benzinga
CERo Therapeutics Holdings Inc (CERO)’s stock price range in the last year - uspostnews.com
CERo Therapeutics begins Phase 1 trial for AML treatment - Investing.com
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon - GlobeNewswire
Major Blood Cancer Center Joins CERo's Novel AML Treatment Trial, June Dosing Planned - Stock Titan
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Boral Capital sets Cero Therapeutics stock with Buy rating - Investing.com Australia
CERo Therapeutics secures $8 million in funding for cancer therapy By Investing.com - Investing.com South Africa
What Are You Thinking About Investing In CERo Therapeutics Holdings Inc (NASDAQ: CERO) Stock? - Stocksregister
CERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy Programs - Nasdaq
D. Boral Capital Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq
Boral Capital sets Cero Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
CERo Therapeutics secures $8 million in funding for cancer therapy - Investing.com Australia
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing - The Manila Times
CERo Therapeutics Holdings, Inc. Announces $8 Million Securities Purchase Agreement to Advance Immunotherapy Development - Nasdaq
CERo Therapeutics Lands $8M Series D Funding: FDA-Cleared Cancer Trials at MD Anderson Set to Launch - Stock Titan
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing - ADVFN
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236 - ADVFN
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting - ADVFN
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - ADVFN
Insider Sale Alert: CERo Therapeutics Holdings Inc [CERO] – Is it Time to sell? - knoxdaily.com
CERO THERAPEUTICS HOLDINGS, INC. SEC 10-K Report - TradingView
CERO stock plunges to 52-week low of $0.64 amid market challenges By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low of $0.64 amid market challenges - Investing.com Canada
CERo Therapeutics expands patent portfolio for cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics expands patent portfolio with new US approvals By Investing.com - Investing.com South Africa
Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office - marketscreener.com
CERo Therapeutics expands patent portfolio for cancer therapy - Investing.com Australia
CERo Therapeutics expands patent portfolio with new US approvals - Investing.com
CERo Therapeutics Holdings, Inc. Announces Critical Patent - GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. - Bluefield Daily Telegraph
Breakthrough: CERo's Cancer Drug Patents Lock in Protection Until 2039 - Stock Titan
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia - The Katy News
CERo Therapeutics Holdings, Inc. Announces Initial Clinical - GlobeNewswire
0.01%
2.96%
大文字化:
|
ボリューム (24 時間):